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ABSTRACT
Objectives Antiretroviral therapy (ART) availability in a
population may inﬂuence risky sexual behaviour. We
examine the potential impact of ART on the HIV
epidemic, incorporating evidence for the impact that ART
may have on risky sexual behaviour.
Methods A mathematical model, parameterised using
site-speciﬁc data from Uganda and worldwide literature
review, was used to examine the likely impact of ART on
HIV epidemiologic trends. We varied assumptions about
rates of initiating ART, and changes in sexual partner
turnover rates.
Results Modelling suggests that ART will reduce HIV
incidence over 20 years, and increase prevalence. Even in
the optimistic scenario of ART enrollment beginning after
just ﬁve months of infection (in HIV stage 2), prevalence
is estimated to rise from a baseline of 10.5% and 8.3%
among women and men, respectively, to at least 12.1%
and 10.2%, respectively. It will rise further if sexual
disinhibition occurs or infectiousness while on ART is
slightly higher (2% female to male, rather than 0.5%).
The conditions required for ART to reduce prevalence
over this period are likely too extreme to be achievable.
For example, if ART enrolment begins in HIV stage 1
(within the ﬁrst 5 months of infection), and if risky
sexual behaviour does not increase, then 3 of our 11
top ﬁtting results estimate a potential drop in HIV
prevalence by 2025. If sexual risk taking rises, it will
have a large additional impact on expected HIV
prevalence. Prevalence will rise despite incidence falling,
because ART extends life expectancy.
Conclusions HIV prevalence will rise. Even small
increases in partner turnover rates will lead to an
additional substantial increase in HIV prevalence. Policy
makers are urged to continue HIV prevention activities,
including promoting sex education, and to be prepared
for a higher than previously suggested number of HIV
infected people in need of treatment.
INTRODUCTION
Antiretroviral therapy (ART) use is now widespread
in sub-Saharan Africa.1 Recent evidence suggests
that ART may reduce population-level incidence of
HIV.2 Modelling studies have also investigated the
potential impact of ART.3–12 These studies have
reached varying conclusions. Treatment prolongs
the lives of those infected, so some studies have
suggested increased prevalence due to ART.6 9 13
However, it has also been suggested that frequent
testing and early ART enrolment could reduce HIV
prevalence,7 8 10 and may even eradicate the epi-
demic.10 14 HIV-infected individuals on ART are
less infectious than those not on ART.15–17 The dif-
fering conclusions are largely dependent on
assumptions, and may be particularly sensitive to
assumptions about sexual behaviour.12 ART may
lead to sexual disinhibition as people feel that they
may live a long life with HIV.
The overall impact that ART may have on the
HIV epidemic sometimes incorporates the potential
impact of ART on sexual behaviour.6 10 However,
the ranges of potential behaviour change are often
not based on data, and do not include the impact
that ART availability may have on behaviour among
HIV uninfected people. Previous studies have pro-
vided contrasting results regarding the impact of
ARTon sexual behaviour.18–20
Previously, we examined self-reported evidence
for changing sexual behaviour after the introduc-
tion of ART in a rural Ugandan cohort in 2004.21
We found evidence that risky behaviour, particu-
larly partner turnover rates, may rise among HIV
uninfected people in response to the availability of
ART.
In the Ugandan cohort mentioned above, HIV
prevalence rose from 6.87% in 2004, the year that
ART roll-out began, to 8.75% by 2012. However,
in this cohort, most people do not begin ART treat-
ment until HIV stage 3.
Here, through mathematical modelling, we assess
the plausible impact of ART on future HIV preva-
lence and incidence under different scenarios of
rate of ART enrolment. As some have postulated
that ART may be a means of eradicating HIV,10 14
our objective is to assess whether ART could con-
ceivably reduce or eliminate the HIV epidemic,
under extremely optimistic conditions. We examine
impact in a range of scenarios with varying assump-
tions about the average time from HIV infection
until ART enrolment, infectiousness while on ART,
and sexual behaviour modiﬁcation. Uniquely in this
study, we incorporated evidence-driven potential
sexual behaviour change due to ART among people
infected with HIV, as well as due to the availability
of ARTamong those uninfected with HIV.
METHODS
In 1989, the Medical Research Council established
a general population cohort (GPC) in rural
Uganda.22–24 Participants are serotested annually
for HIV. We present HIV prevalence estimates from
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this cohort, following estimation methods described previ-
ously.25 26 We ﬁt our model to prevalence data through 2004,
which is the last year in which the impact of ART on epidemio-
logic trends would not yet have been felt in this population.
Mathematical model
The compartmental mathematical model is stratiﬁed by age, sex
and sexual activity group (ﬁgure 1). Details are online (see
online supplementary appendix). Results are based on simula-
tions with average durations in HIV stages 1–4 of 5 months,
7 years, 18 months and 10 months.
Upon ARTenrolment in the model, infectiousness drops. At a
rate of 0.5/year, those who have not yet died move into a com-
partment with mortality rate equivalent to background mortal-
ity. It is assumed that after surviving the initial ART period, life
expectancy on ART is the same as that among HIV uninfected
people.
Baseline scenario
The baseline scenario was ﬁt to data from Uganda and literature
reviews. We ﬁt to empirically estimated HIV prevalence by
gender among 15–54-year-olds from 1991 to 2004, before ART
can have impacted prevalence. To ﬁt, we ran 750 000 simula-
tions with varying parameter values (see online supplementary
table S1). Parameters include behaviour change before the intro-
duction of ART, consistent with evidence suggesting that risky
behaviour declined during the 1990s.27 The parameter set with
the highest goodness of ﬁt between model and empirically esti-
mated prevalence was considered the best ﬁtting.
ART impact scenarios
ART introduction was simulated in 2004. We examined six ART
scenarios (table 1).
Within each of the ﬁrst four scenarios, we varied the annual
rate of ART enrolment once the respective HIV stage was
reached, from 0.0 (baseline—no ART) to 1.0. In these scenarios,
we assumed that partnership turnover rates did not change after
ART introduction. We examined two scenarios in which ART
enrolment may begin as early as HIV stage 1, and two in which
ART enrolment may begin in HIV stage 3. We present the
Figure 1 Compartmental Mathematical Model (Enclosed in parentheses are the symbols used in the differential equations.)
Table 1 ART Impact Scenarios
Scenario
Probability of HIV
transmission while
on ART (per
partnership)
Earliest HIV stage of
ART enrolment
Modelled change
in sexual partner
turnover?
1 0.5% F->M,
1.0% M->F
3 (rate of initiation
varies)
No
2 2.0% F->M,
4.0% M->F
3 (rate of initiation
varies)
No
3 0.5% F->M,
1.0% M->F
1 (rate of initiation
varies)
No
4 2.0% F->M,
4.0% M->F
1 (rate of initiation
varies)
No
5 0.5% F->M,
1.0% M->F
2 (rate of
initiation=0.9/year)
Yes
6 2.0% F->M,
4.0% M->F
2 (rate of
initiation=0.9/year)
Yes
ART, antiretroviral therapy.
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scenarios of ARTenrolment beginning in stages 1 and 3 as these
are boundaries. It may be unlikely to expect ART enrolment in
stage 1 often enough to impact the epidemic, but we present
this scenario as it represents the upper bound of the impact that
ART could possibly have on the HIV epidemic.
When examining the impact of increasing partner turnover
rates in response to ART availability, it was assumed that ART
enrolment may begin as early as HIV stage 2, and that the enrol-
ment rate was 0.9/year. The percent increase in partner turnover
rate beginning in 2004 varied from 0.0% (no change) to 50.0%.
HIV stage 2 represents a reasonable yet aggressive timing for
ARTenrolment.
When HIV transmission while on ART was 1% male to
female (0.5% female to male), this represented a percent reduc-
tion in transmission probability in our best ﬁtting scenario
among men ranging from 85.1% to 96.6%, and among women
ranging from 90.9% to 97.6%. The percent reduction depended
on the stage from which ARTwas initiated, and the probability
of transmission from the respective stage before ARTenrolment.
Goodness-of-ﬁt measures and sensitivity analysis
We assessed the sensitivity of results to parameter value set
selection by summarising the results from multiple good
ﬁtting parameter sets: We found the best ﬁtting parameter
values using three goodness-of-ﬁt (GoF) measures: a sum of
squares, a χ2,28 and maximum likelihood.29 30 We used three
GoF measures because some readers may be more conﬁdent
in results of one or another of the measures, but the three
measures produced signiﬁcantly overlapping best ﬁts.2 We
compared results using the ﬁrst through seventh best ﬁtting
parameter sets.
Of the 21 sets of parameter values, 10 were repeats. That
is, ﬁve of the seven best ﬁtting sets found when maximising
the likelihood function were the same as those found when
Figure 2 Sensitivity Analyses of Dual Impact of antiretroviral therapy (ART) and Potential Behavior Change on HIV Prevalence.
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minimising the sum of squared differences, and ﬁve of those
found under the χ2 GoF had also been found under either
the sum of squares or maximum likelihood GoF. We used the
remaining 11 parameter sets to assess robustness of model
results.
RESULTS
In the best ﬁt, HIV transmission probability per partnership and
stage is shown in online supplementary table S1.
Prevalence
Among the 11 best ﬁtting simulations, we obtained model-
estimated prevalence continuously from 1975 to 2025. The
mean of these model estimates is presented in ﬁgure 2, for a
range of different scenarios. Panels A and B correspond to scen-
ario sets 1 and 2, described in methods. With no ART, HIV
prevalence reaches 10.5% among women and 8.3% among men
by 2025. In panel A, if the rate of ART enrolment beginning in
stage 3 is 0.25/year, then predicted HIV prevalence rises to
12.0% among women and 9.5% among men by 2025. Panel B
portrays a scenario set in which the drop in the probability of
HIV transmission while on ART is less than that in panel A. In
this case, under an otherwise similar scenario to that just
described, prevalence rises to 12.9% among women and 10.2%
among men by 2025. The increase in HIV prevalence is more
pronounced in these scenarios if people begin ART at a faster
rate. If ART enrolment beginning in HIV stage 3 is 1.0/year,
then HIV prevalence may rise to 15.5% among women and
12.2% among men by 2025 (panel B).
In scenario set 3, people initiate ART in HIV stage 1, and
there is no behaviour change in response to ART availability.
This is the only one among the range of scenarios examined in
which the average of our 11 best ﬁtting prevalence estimates
indicates that HIV prevalence may initially fall after ART intro-
duction (ﬁgure 2C). By 10 years after ART is introduced,
among men, HIV prevalence is higher if the rate of ART enrol-
ment is less than 0.50/year than it would have been in the
absence of ART, and among women it is higher regardless of
ART enrolment rates. However, among men, if the rate of ART
enrolment is greater than 0.50/year, and ART enrolment begins
in HIV stage 1, then HIV prevalence may permanently decline,
relative to what it is in the absence of ART. If the rate of ART
enrolment is 1.0/year, HIV prevalence falls to 10.5% among
women and 7.4% among men by 2015, before rising to 11.4%
among women by 2025 and remaining level among men. Panel
D (scenario set 4) portrays a similar scenario set, except that the
drop in probability of HIV transmission while on ART is less. In
this case, the impact of ART is to increase HIV prevalence dra-
matically, regardless of the rate at which people initiate ART.
We next examined the impact that ART may have on HIV
prevalence if partner turnover rates increase. The scenarios
depicted in ﬁgure 2E,F, are described as scenario sets 5 and 6 in
methods. In panel E, a 12.5% increase in partner turnover rate
results in rising HIV prevalence up to 20 years after ART is
introduced. By 2025, prevalence reaches 17.7% among women
and 13.9% among men, contrasting with 12.1% (women) and
10.2% (men) without behaviour change. If ART only reduces
HIV transmission probability per partnership to 2% female to
male (panel F), then prevalence is higher, but the relative
impact of higher partner turnover rates is similar to what it is
under the scenario in which ART reduces HIV transmission
probability to 0.5% female to male.
As anticipated, we estimated increasing HIV prevalence in the
presence of ART even when most of the HIV infected are on
ART. In ﬁgure 2EF, the rate of initiating ART was 0.9/year,
beginning in stage 2. In this case, the percent of HIV infected
who are on ART reaches almost 90% by 20 years after the intro-
duction of ART in the population.
Sensitivity analysis
Multiple sets of parameter values produced model estimates that
ﬁtted the empirically estimated prevalence. Without ART, the 11
sets of parameter values that most closely ﬁt our data estimated
similar HIV epidemics (ﬁgure 3).
By 2025, all 11 sets of parameter values estimated that ART
would result in increased HIV prevalence, if ART enrolment
begins in HIV stage 3 (table 2, scenario 1). The smallest increase
in prevalence would occur if the probability of HIV transmis-
sion per partnership female to male was low at 0.5%, and the
rate of ARTenrolment was also low at 0.25/year. In this case, by
2025, the mean increase in prevalence was 14.6% (table 2, scen-
ario 1). If either the rate at which people begin ART treatment
or the probability of HIV transmission while on treatment rises,
then all 11 parameter sets estimated an even greater rise in HIV
prevalence than under the scenario just described.
Figure 3 Prevalence by Gender–Age
15–54 Markers-Uganda Cohort Data,
Lines-Model.
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In the extreme scenario in which ARTwas initiated beginning
during HIV stage 1, HIV transmission probability on ART
female to male was 0.5%, and there was no behaviour change,
the estimated impacts from the 11 parameter sets were incon-
sistent. Three of the sets suggested a drop in HIV prevalence by
2025, while eight suggested an increase. Across all parameter
sets, the mean change in HIV prevalence over the scenario of
no ARTwas a 24.7% rise assuming that the rate of ART enrol-
ment was 0.25/year and a 9.8% rise if the rate of ART enrol-
ment was 1.00/year (table 2, scenario 3). If the probability of
transmission while on ARTwas 2% female to male, all but one
of the modelled parameter sets indicated that ARTwould result
in rising HIV prevalence (table 2, scenario 4).
Not surprisingly, all sets of parameter values suggested that an
increase in partner turnover rate would result in rising HIV
prevalence. For example, if the probability of HIV transmission
while on ARTwas just 0.5% female to male, and ARTenrolment
began in stage 2 at a very high rate of 0.9/year, then the mean
increase in prevalence by 2025 caused by a 12.5% increase in
partner turnover rate was 10.1% (table 2, scenario 5).
Incidence
Without behaviour change, ARTreduces HIV incidence (ﬁgure 4).
This assumes a high rate of ARTenrolment beginning in HIV stage
2, and that ART lowers the probability of HIV infection per part-
nership to 0.5% female to male and 1% male to female. Without
behaviour change, our model suggests that ARTwould lower inci-
dence from 14.7 to 8.9 per 1000 person-years observation (pyo)
among men, and from 19.3 to 13.7 among women. If average
partner turnover rate increases by 12.5%, then our results indicate
that the dual impact of ART and behaviour change would lower
incidence to 10.3 per 1000 pyo among men, and to 15.3 among
women. If partner turnover rate increases by 50%, then incidence
would initially rise, but would then stabilise at approximately the
same values as without ART.
Table 2 Percent increase in HIV prevalence forecasted by 11 ‘best fit’ parameter value sets, under scenarios depicted in figure 2 (% increase
compared to scenario of no ART or no behaviour change)
Modelled parameter value set
Scenario Year 1 2 3* 4 5 6 7 8 9 10* 11* Mean (SD)
Probability of transmission on ART=0.5% female to male. No ART enrolment in HIV stages 1 or 2 (figure 2A)
Rate of ART init starting stage 3
0.25/year 2015 1.3 11.2 0.4 −0.4 7.4 6.0 13.0 10.2 10.6 9.3 12.7 7.4 (4.9)
2025 6.5 19.3 5.5 4.5 14.3 14.2 20.7 19.4 18.4 16.9 21.4 14.6 (6.3)
1.00/year 2015 1.8 23.4 −0.2 −3.7 14.4 11.5 28.6 21.8 23.2 20.2 27.9 15.4 (11.5)
2025 9.9 39.0 7.9 1.6 26.8 27.2 43.7 39.5 38.2 33.9 45.0 28.4 (15.4)
Probability of transmission on ART=2.0% female to male. No ART enrolment in HIV stages 1 or 2 (figure 2B)
Rate of ART init starting stage 3
0.25/year 2015 6.6 14.8 4.9 2.5 15.5 14.8 17.8 17.6 16.2 16.8 15.0 13.0 (5.5)
2025 16.7 24.1 13.9 10.4 25.8 27.1 27.0 31.5 26.2 31.2 24.7 23.5 (6.9)
1.00/year 2015 14.2 32.6 10.6 3.3 34.7 32.8 39.7 39.1 36.1 36.8 33.6 28.5 (12.7)
2025 32.9 50.9 27.5 15.5 55.5 57.1 58.8 66.2 56.4 64.8 53.2 49.0 (16.3)
Probability of transmission on ART=0.5% female to male. ART enrolment begins in HIV stage 1 (figure 2C)
Rate of ART init
0.25/year 2015 −10.7 21.9 −10.7 −19.0 13.4 14.0 21.1 15.6 21.8 2.7 23.3 8.5 (15.4)
2025 −4.1 44.7 −4.3 −21.5 30.1 37.5 42.3 39.4 44.2 14.4 49.2 24.7 (24.5)
1.00/year 2015 −30.9 17.1 −25.2 −33.6 6.7 10.9 17.2 7.7 24.5 −3.9 18.8 0.8 (21.2)
2025 −41.1 35.5 −25.5 −46.8 12.0 27.4 32.2 21.6 47.5 1.2 43.7 9.8 (33.6)
Probability of transmission on ART=2.0% fem ale to male. ART enrolment begins in HIV stage 1 (figure 2D)
Rate of ART init
0.25/year 2015 16.0 44.2 12.2 −4.5 61.0 58.8 50.4 56.0 53.3 36.0 39.7 38.4 (21.6)
2025 42.7 72.8 36.5 6.2 98.5 102.0 81.2 98.7 87.9 74.1 71.0 70.1 (30.1)
1.00/year 2015 17.2 69.9 14.7 −12.9 102.2 96.6 80.0 89.3 85.7 52.2 61.3 59.7 (37.9)
2025 41.2 105.0 41.1 −10.6 151.5 153.9 119.2 143.1 129.8 95.5 100.4 97.3 (52.7)
Probability of transmission on ART=0.5% female to male. ART enrolment begins in stage 2 at rate 0.9/year (figure 2E)
Change partner turnover rate
Increase by 12.5% 2015 10.3 6.4 7.1 9.6 10.9 8.8 7.5 8.5 6.2 6.6 6.0 8.0 (1.7)
2025 14.5 6.3 10.0 16.2 14.7 10.4 8.0 9.9 6.5 9.2 5.5 10.1 (3.6)
Increase by 50% 2015 43.2 19.9 32.9 65.6 40.9 34.4 25.0 31.0 24.0 30.9 20.6 33.5 (13.1)
2025 58.7 19.2 45.7 110.0 48.0 36.1 25.4 33.9 24.1 43.2 18.6 42.1 (25.9)
Probability of transmission on ART=2.0% female to male. ART enrolment begins in stage 2 at rate 0.9/year (figure 2F)
Change partner turnover rate
Increase by 12.5% 2015 9.8 3.1 8.0 12.0 6.1 6.0 3.7 5.2 5.0 8.4 3.5 6.4 (2.8)
2025 12.0 2.9 9.5 18.7 6.0 6.2 3.9 5.1 4.9 10.5 3.6 7.6 (4.7)
Increase by 50% 2015 41.6 11.6 35.1 71.1 24.8 24.8 14.4 20.6 20.7 38.7 12.9 28.8 (17.4)
2025 47.8 10.8 39.2 101.2 23.4 25.1 15.3 20.2 19.4 47.8 13.1 33.0 (26.1)
*Though parameter value sets 3, 10, and 11 provided good model fits to empirically estimated prevalence, we believe they are less likely than the others because they estimated the
HIV epidemic peaking too early (see figure 3).
ART, antiretroviral therapy.
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In the ﬁgure 4 scenario, with no behaviour change, 18.4% of
incidence by 2025 comes from people in stage 1, 6.6% from
people in stage 2, and 73.4% from people on ART. Just 1.6% of
incidence comes from people in stages 3 and 4. By contrast, in
the same scenario but in the year prior to ART introduction,
36.2% of incidence comes from people in stage 1, 40.3% from
stage 2, 16.5% from stage 3 and 7.0% from stage 4. The lower
percent of incidence in stage 4 despite high infectiousness
results from: a reduction in partner turnover rate in stage 4 (see
online supplementary table S1), and mortality before stage 4
such that some people never reach this stage.
DISCUSSION
Epidemiologic forecast
Recent evidence from clinical trials have shown the positive
impact that ART may have on reducing new infections (inci-
dence).2 Our modelling work supports this evidence by also
showing a reduction in incidence, unless partner turnover rates
increase greatly (>50%). However, although incidence falls,
results suggested that HIV prevalence will be higher with ART
than without. Among the scenarios examined, HIV prevalence
may decrease among men only in an extreme case which may
not be achievable in practice. That is, ART enrolment would
need to begin while still in HIV stage 1, the rate of ART enrol-
ment would need to be greater than 0.50/year, sexual partner
turnover would not change, and the probability of transmission
while on ARTwould be just 0.5% per partnership from female
to male (representing >95% reduction in transmission com-
pared to no ART). Even in this case, 8 of the 11 sets of param-
eter values that we assessed suggested that HIV prevalence
would be higher in the presence of ART than in its absence.
Despite the short duration in the initial HIV stage of infec-
tion, our model estimates that in the absence of ARTabout 36%
of incidence comes from partnerships formed in which the
HIV-infected partner was in the highly infectious stage 1.
Initiating ART during this stage, if feasible, would therefore
have the greatest impact on the epidemic.
Previous studies have suggested a range of potential outcomes
to rolling out ART, from increasing6 9 13 to decreasing HIV
prevalence.7 8 10 14 Although our work supports this range of
potential outcomes to rolling out ART, in all but the most
extreme scenarios our results consistently suggest that HIV
prevalence will rise as a result of ART.
Results from this study come from a model that was parame-
terised and ﬁt using data from Uganda. We expect that our
results provide a good estimate of the impact of ART and corre-
sponding sexual behaviour change on HIV epidemiologic trends
in countries that are similar to Uganda in terms of HIV preva-
lence trends pre-ART and HIV modes of transmission (mainly
heterosexual sex).
Limitations
Results of any modelling study may be inﬂuenced by model
assumptions. We have described our model assumptions in
detail in the online supplementary appendix. One model
assumption was that of no HIV/AIDS-related mortality after the
initial period on ART. This is likely overly optimistic as non-
perfect ART adherence speeds HIV progression and a higher
mortality rate. If we had modelled a slightly higher mortality
rate, even among those on ART, then estimated HIV prevalence
after ART is introduced would be lower, as infected people
would die at a higher rate. Also, we used a deterministic math-
ematical model. As such, stochastic events that may inﬂuence
the plausible range of the impact of ART on HIV prevalence
and incidence were not modelled.
In our best ﬁtting model simulation, 36.2% of HIV incidence
prior to ART introduction came from people in HIV stage 1.
While this is similar to that estimated elsewhere,31 32 it is higher
than that estimated by some.33 If more HIV incidence is attrib-
utable to higher HIV stages than we estimated, then ART enrol-
ment in later stages would have a greater impact on incidence
and subsequent prevalence.
CONCLUSION
It is unlikely that most HIV infections could be identiﬁed during
the high viraemic stage 1 of infection. If infections are identiﬁed
at a rate of 0.9/year beginning in stage 2, and ART is initiated
immediately after detection, our results indicate that HIV inci-
dence would fall as a result of ART. However, this comes at a
cost. Our results still indicate rising prevalence as those infected
live longer. The combined effect of increased risky sexual behav-
iour and longer life expectancy while infected would increase
HIV prevalence dramatically. Care providers should be prepared
Figure 4 Incidence among age
15–54 antiretroviral therapy (ART)
initiation rate=0.9/year beginning in
HIV stage 2. Rate of movement from
high to low mortality on ART=0.5/year.
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for a higher than previously suggested11 number of people who
are likely to need treatment.
Key messages
▸ Although HIV incidence will fall, HIV prevalence will rise as
a result of antiretroviral therapy.
▸ If the possible increase in risky sexual behaviour is not
controlled, HIV prevalence will rise even further.
▸ Policy makers must prepare to provide care for the increased
population living with HIV.
▸ Policy makers are urged to continue HIV prevention
activities, including promoting sex education.
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